Feed CHJTF
CH

CSPC Pharmaceutical Group Limited

CHJTF · OTC

$1.11 +0.00% (+$0.00)
Market Cap ¥84.8B
P/E Ratio 22.43x
Div. Yield 3.43%
ROE 11.09%

Bulios Fair Price

$0.79

28.8% downside

Current Price

$1.11

Undervalued Fair Value Overvalued

According to Bulios Fair Price, CHJTF is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
56 /100
Fair
P/E 22.43x
P/FCF 21.27x
EV/EBITDA 15.14x
Growth
4 /100
Declining
EPS growth 14.06%
Book val. growth 3.68%
Rev. growth 6.45%
Profitability
84 /100
Strong
Gross margin 65.59%
FCF margin 15.74%
Net margin 14.93%
Quality
52 /100
Average
ROIC 8.43%
Asset turnover 0.54x
ROE 11.09%
Debt
100 /100
Low
Debt/Equity 0.02x
Net debt/EBITDA -1.04x
Current ratio 2.19x
Stability
91 /100
Stable
Beta 0.79x
Profitable years 6
Rev. volatility 15.27%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CHJTF
Online

About the company

CSPC Pharmaceutical Group Limited is a major Chinese pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company operates in three main segments: finished drugs, bulk drugs, and functional foods. CSPC focuses on innovative drugs, with key therapeutic areas including nervous system diseases, oncology, anti-infectives, and cardiovascular diseases.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Lei Cai

Employees

19,700

Headquarters

Shijiazhuang

Upcoming events

20 OCT

Ex-Dividend

Ex-dividend date

35d
10 NOV

Dividend Payment

Payment date

56d
19 NOV

Earnings

Upcoming earnings report

65d
24 MAR

Earnings

Upcoming earnings report

190d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.